Perspective Therapeutics (CATX) Operating Expenses (2010 - 2026)

Perspective Therapeutics has disclosed Operating Expenses across 17 years of filings, most recently posting $29.3 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 20.59% year-over-year to $29.3 million; the TTM figure through Jun 2026 stood at $104.2 million (down 5.89% YoY), while the FY2025 annual figure was $114.4 million, up 23.94% from the prior year.
• Operating Expenses came in at $29.3 million for Q2 2026 at Perspective Therapeutics, up from $28.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.2 million in Q4 2024 to a low of $2.8 million in Q1 2022.
• Average Operating Expenses over 5 years is $16.5 million, with a median of $12.7 million recorded in 2023.
• Year-over-year, Operating Expenses dropped 4.25% in 2023 and surged 276.41% in 2024.
• Over 5 years, Operating Expenses stood at $5.6 million in 2022, then surged by 113.72% to $12.0 million in 2023, then surged by 276.41% to $45.2 million in 2024, then slumped by 46.2% to $24.3 million in 2025, then gained by 20.59% to $29.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $29.3 million in Q2 2026, $28.4 million in Q1 2026, and $24.3 million in Q2 2025.